Drug Monograph

Drug Name:	**Gimoti™ (metoclopramide) Nasal Spray**
Drug Class:	**Gastrointestinal: Antiemetics, 5-HT3, NK1 & Other Select Non-Injectable Agents**
Prepared For:	MO HealthNet
Prepared By:	Conduent

☒ **New Criteria** ☐ **Revision of Existing Criteria**

Executive Summary

Purpose:	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.
Dosage Forms:	Gimoti is available in a 9.8 ml bottle containing 15 mg/actuation nasal spray.
Manufacturer:	Manufactured for: Evoke Pharma, Inc., Solana Beach, CA 92075.
Indications:	Gimoti is a dopamine-2 (D_2) antagonist indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis.
Costs:	$1,750 per 9.8 ml bottle of Gimoti. Wholesale Acquisition Cost
Summary of Findings:	This drug is being considered for inclusion in the state specific Preferred Drug List (PDL) as non-preferred

Status Recommendation:	☐ Clinical Edit	☐ PA Required
	☐ Open Access	☒ PDL
Type of PA Criteria:	☐ Appropriate Indications	☒ Non-Preferred
	☐ No PA Required	☐ Preferred

Prepared by: April Ash, PharmD.
Date: February 3, 2021

© 2021 Conduent Business Services, LLC All Rights Reserved.